JPH203 NEW
| Price | $43 | $59 | $84 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: JPH203 | CAS No.: 1037592-40-7 |
| Purity: 98.29% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | JPH203 |
| Description | JPH203 (KYT-0353) is a potent and specific inhibitor of L-type amino acid transporter protein 1 (LAT-1). JPH203 inhibits cellular uptake of leucine, inhibits cell proliferation, induces apoptosis, and possesses anti-inflammatory and anti-tumor activities. |
| Cell Research | Growth inhibition is evaluated by the MTT assay method. Namely, cell suspensions (1 × 10^4 cells/mL) in a volume of 135 μL are placed into the wells of a flat-bottom 96-well microtiter plate and incubated in the atmosphere of 5% CO2 at 37°C (24 h). Drug solutions (15 μL) at various concentrations are added and incubated (96 h) under the same conditions. Next, MTT (15 μL, 5 mg/mL) dissolved in PBS is added and incubated (4.0 h). The incubation medium containing MTT is aspirated off. Cells are mixed (5 min) with DMSO (200 μL) and optical density read (540 nm) using a microtiter plate reader Emax. Subsequently, IC50 values are determined [1]. |
| Animal Research | HT-29 tumor blocks are injected subcutaneously to the right flank of male nude mice. After tumor volumes reach 100 to 300 mm3, the mice are divided into groups (n = 6). On the day of grouping (day 0), JPH203 is administered intravenously daily for 14 days at three different doses (6.3, 12.5, and 25.0 mg/kg). Tumor volumes and body weights are measured two or three times a week for 42 days. Tumor volumes are expressed relative to initial tumor volume (day 0). Growth inhibition ratios for each treatment group is obtained from the mean tumor volume of the treated group compared to that of the control group [1]. |
| In vitro | METHODS: HT-29, S2-LAT1 and S2-LAT2 cells were incubated with medium containing 14C-leucine and JPH203 (0.01-10 μM) for 1.0 min, and the radioactivity of cell lysates was counted using a scintillation counter. RESULTS: JPH203 inhibited 14C-leucine uptake by S2-hLAT1 cells in a concentration-dependent manner, with an IC50 of 0.14 μM. JPH203 barely inhibited 14C-leucine uptake by S2-hL cells, and thus had a high in vitro hLAT1 inhibition selectivity. [1] METHODS: Human osteosarcoma cells Saos2 and human osteoblasts FOB were treated with JPH203 (0.01-30 mM) for 1-4 days, and cell viability was detected by MTT Assay. RESULTS: JPH203 effectively inhibited cell proliferation in a dose- and time-dependent manner in Saos2 cells.JPH203 only slightly inhibited the proliferation of FOB cells. [2] |
| In vivo | METHODS: To test the antitumor activity in vivo, JPH203 (6.5-25 mg/kg) was injected intravenously into nude mice bearing human colorectal cancer tumor HT-29 once daily for 14 days. RESULTS: JPH203 inhibited tumor growth in a dose-dependent manner. The maximum inhibition rates at 6.3, 12.5 and 25.0 mg/kg were 58.2% (day 42), 65.9% (day 30) and 77.2% (day 38), respectively. [1] METHODS: To test the antitumor activity in vivo, JPH203 (50 mg/kg in SBECD) was injected intraperitoneally into a matrix-enriched CRC mouse model once daily for fourteen days. RESULTS: JPH203 treatment significantly reduced tumor size and metastasis, and RNA sequencing-based pathway analysis showed that not only tumor growth and amino acid metabolism pathways, but also stromal activation-related pathways were inhibited. [3] |
| Storage | store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 100 mg/mL (211.7 mM), Sonication is recommended. 5%TFA : 2.31 mg/mL (4.89 mM), Heating at 50℃ is recommended. 5% DMSO+40% PEG300+5% Tween 80+50% Saline : 5 mg/mL (10.59 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. |
| Keywords | JPH 203 | JPH203 | KYT 0353 | KYT0353 | JPH-203 |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $109.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY